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Opportunities to treat infection with hepatitis C virus
(HCV) are evolving rapidly. From the introduction of
interferona monotherapy in the early 90s’ to the approval
of telaprevir and boceprevir based triple therapies with
pegylated interferona and ribavirin in 2011, the chances
of curing patients infected with HCV genotype 1 have
improved dramatically to reach approximately 70%. Sig-
nificant further improvements, which may cure virtually
all hepatitis C patients with an all oral, interferon-free
regimen will become available in the very near future.
These new direct acting antivirals (DAA) target the viral
polymerase with either nucleoside analogues or non
nucleosidic inhibitors, the viral protease, and the viral
NS5A protein. Several clinical trials have now shown that
a combination of sofosbuvir (nucleosidic polymerase
inhibitor) with daclatasvir or ledipasvir (NS5A inhibi-
tors), or sofosbuvir with simeprevir (protease inhibitor),
or a combination of ABT-450 (proease inhibitor) with
ritonavir (ABT-450/r), the nonnucleoside polymerase
inhibitor ABT-333 and the NS5A inhibitor ABT-267, can
achieve sustained virologic response in up to 95% of
naive patients or previously treated patients, even in
patients who failed prior treatment with first generation
protease inhibitor. As these DAAs are becoming available
in early access treatment programs, treatment strategy
studies are being performed to optimize treatment regi-
mens with respect to the choice of DAAs and treatment
duration, based on viral genotypes, prior treatment expo-
sure, and the presence of liver cirrhosis. The next chal-
lenge will be to identify HCV infected patients in the
general population and to facilitate access to treatment.
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